MedTrace Logo

ATAPAC Study (TauroLock Activity in Adult Cancer Patients)

NCT02279121 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2016-08-26

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of a lock taurolidine-citrate solution vs standard saline solution for primary prevention of central venous catheter-associated bloodstream infection in adult patients treated with intra-venous therapy for a solid tumor

Conditions

  • Catheter-Related Infections

Interventions

DEVICE

Taurolock

At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study

DRUG

saline solution

At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study

Sponsors & Collaborators

  • centre régional de pharmacovigilance de Nancy

    collaborator UNKNOWN

  • Theradial

    collaborator INDUSTRY

  • Centre Hospitalier Régional Metz-Thionville

    lead OTHER

Principal Investigators

  • Raffaele LONGO, MD · CHR Metz Thionville

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02279121 on ClinicalTrials.gov